Seaport Therapeutics Seeks $912 Million Valuation in Nasdaq IPO
Seaport Therapeutics, a clinical-stage biotechnology company based in Boston, has filed for a U.S. initial public offering that would value the company at $912 million. The firm is proposing to sell 11.8 million shares at $16 to $18 each to raise up to $212.4 million, and plans to list on the Nasdaq Global Market under the symbol SPTX. The filing c…